Robert Adams to Hydroxyurea
This is a "connection" page, showing publications Robert Adams has written about Hydroxyurea.
Connection Strength
0.825
-
Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016 Feb 13; 387(10019):661-670.
Score: 0.493
-
Hydroxycarbamide treatment reduces transcranial Doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial Doppler velocity, and cerebral vasculopathy: the EXTEND trial. Br J Haematol. 2021 11; 195(4):612-620.
Score: 0.182
-
Stroke prevention and treatment in sickle cell disease. Arch Neurol. 2001 Apr; 58(4):565-8.
Score: 0.045
-
Ischemic stroke in children and young adults with sickle cell disease in the post-STOP era. Am J Hematol. 2019 12; 94(12):1335-1343.
Score: 0.040
-
Developing a risk-based composite neurologic outcome for a trial of hydroxyurea in young children with sickle cell disease. Clin Trials. 2019 02; 16(1):20-31.
Score: 0.038
-
Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood. 2014 Aug 07; 124(6):891-8.
Score: 0.028